How to read a peptide study without overreading the result
A result from a peptide study answers a narrow question: who was studied, how many, for how long, compared with what, and what was measured. Most human studies of the peptides sold online are very small, and many have no comparison group. A 2026 review of BPC-157 found three human studies with 30 people in total and rated the certainty of evidence very low. Read the design before the headline.
Sources checked against Europe PMC abstracts and FDA/DailyMed label text: Nov 17, 2026; full text not read for abstract-only claims (recheck on publication date)
Quick answer
A result from a peptide study answers a narrow question: who was studied, how many, for how long, compared with what, and what was measured. Most human studies of the peptides sold online are very small, and many have no comparison group. A 2026 review of BPC-157 found three human studies with 30 people in total and rated the certainty of evidence very low. Read the design before the headline.
Step 1: Who and how many?

Human peptide study sizes
Check the number of people and who they were. The BPC-157 human studies had 16, 12 and 2 participants. A phase 3 trial of thymosin beta-4 eye drops had 18, and a phase 2 ipamorelin trial had 114 analyzed. Sources: BPC-157 systematic review, 2026; RGN-259 trial; ipamorelin trial. Size alone does not decide quality, but very small studies leave a lot of room for chance.
Step 2: Was there a comparison group?
Randomized trials assign people by chance and are at the top of the usual hierarchy of evidence. Studies without a comparison group cannot show what would have happened without the treatment. The ipamorelin trial was randomized and placebo-controlled and found no significant difference in its key analyses (median time to first tolerated meal 25.3 hours versus 32.6 hours, p = 0.15). Sources: hierarchy of evidence; ipamorelin trial. See the article on trials versus case reports.
Step 3: Animals, cells or people?
Many peptide claims rest on cell or animal studies. The 2026 orthopaedic review says animal findings cannot be assumed to apply in people. Source: narrative review, 2026.
Step 4: What was measured, and for what use?
A trial of eye drops says little about an injection, and a trial in surgery patients says little about muscle recovery. Check the route, the condition and the outcome. A lab marker is not the same as how someone feels or functions.
Step 5: What does the study say about itself?
Look for the authors’ own limits and for who paid. Read the conclusion that the authors wrote, not only a headline or product page.
A “not significant” result is not proof of no effect
In small studies, a p-value above 0.05, such as 0.0656 in the thymosin beta-4 eye drop trial, was described by the authors as a trend. It also does not prove the treatment does nothing. Source: RGN-259 trial.
Questions to bring to a clinician
- What kind of study is this, and who was in it?
- Does it apply to my condition, product and route?
- What does FDA or a label say about this product?
What this does not establish
This page is a reading guide. It does not judge any peptide, and a very small study can still be right.
FAQs
How do I read a peptide study? Check who was studied, how many, the comparison, the route and the outcome.
Does a small study mean the result is wrong? No, but it gives little certainty.
Where should I look for official information? FDA and the product label.